Exelixis, Inc. (EXEL) Announces Second Quarter 2013 Financial Results
8/7/2013 7:22:50 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the quarter ended June 30, 2013.
Q2 2013 Highlights and Recent Events
•Reported net product revenue for COMETRIQ® (cabozantinib) of $4.0 million in the second quarter of 2013.
•Expanded the sales force to 14 representatives.
Hey, check out all the research scientist jobs. Post your resume today!